Cargando…

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor

Detalles Bibliográficos
Autores principales:	Uchida, Naoya, Leonard, Alexis, Stroncek, David, Panch, Sandhya R., West, Kamille, Molloy, Eoghan, Hughes, Thomas E., Hauffe, Sara, Taylor, Tiffani, Fitzhugh, Courtney, Hankins, Jane S., Wilson, Megan, Sharma, Akshay, Tsai, Shengdar Q., Weiss, Mitchell J., Hsieh, Matthew, Tisdale, John F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556661/ https://www.ncbi.nlm.nih.gov/pubmed/33054091 http://dx.doi.org/10.3324/haematol.2019.236182

Ejemplares similares

Plerixafor
por: Slater, Susan
Publicado: (2012)

Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion
por: Lagresle-Peyrou, Chantal, et al.
Publicado: (2018)

Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease
por: Leonard, Alexis, et al.
Publicado: (2022)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

The need for uniform and coordinated practices involving centrally manufactured cell therapies
por: Stroncek, David, et al.
Publicado: (2022)

Choice of Donor Source and Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Sickle Cell Disease
por: Limerick, Emily, et al.
Publicado: (2019)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia
por: Fitzhugh, Courtney D., et al.
Publicado: (2015)

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results
por: Boulad, Farid, et al.
Publicado: (2018)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization
por: Awan, Farrukh T., et al.
Publicado: (2012)

Longitudinal Transcriptional Analysis of Peripheral Blood Leukocytes in COVID Convalescent Donors
por: Gedda, Mallikarjuna Rao, et al.
Publicado: (2021)

βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for Ex Vivo Anti-sickling Activity in Human Erythroid Cells
por: Demirci, Selami, et al.
Publicado: (2020)

Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease
por: Gondek, Lukasz P., et al.
Publicado: (2022)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Is sickle cell disease the same everywhere?
por: Hankins, Jane
Publicado: (2012)

Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy
por: Shao, Lipei, et al.
Publicado: (2022)

Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors
por: Gedda, Mallikarjuna R., et al.
Publicado: (2022)

Illuminating the genome-wide activity of genome editors for safe and effective therapeutics
por: Cheng, Yong, et al.
Publicado: (2018)

Biallelic correction of sickle cell disease‐derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum‐free iPS‐sac/erythroid differentiation
por: Haro‐Mora, Juan J., et al.
Publicado: (2020)

Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
por: Yeral, Mahmut, et al.
Publicado: (2018)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

P2 3-year observation study of Plerixafor use in New Zealand
por: Swinn, Tim, et al.
Publicado: (2021)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Development and validation of a predictive model to guide the use of plerixafor in pediatric population
por: Sebastien, Bernard, et al.
Publicado: (2022)

Decitabine Suspends Human CD34(+) Cell Differentiation and Proliferation during Lentiviral Transduction
por: Uchida, Naoya, et al.
Publicado: (2014)

Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study
por: Kanter, Julie, et al.
Publicado: (2022)

Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease
por: Uchida, Naoya, et al.
Publicado: (2021)

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs
por: Hübel, Kai, et al.
Publicado: (2018)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

141 Sickle cell disease and physical activity: Is it safe?
por: Corvalan Cifuentes, Melissa-Zoraya, et al.
Publicado: (2021)

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
por: Di Maggio, Rosario, et al.
Publicado: (2018)

From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
por: Hankins, Jane S., et al.
Publicado: (2014)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1fbnga5optvad02pql8i20kbs0